CN Patent

CN114728943B — 作为bcr-abl抑制剂的化合物

Assigned to Chia Tai Tianqing Pharmaceutical Group Co Ltd · Expires 2024-12-06 · 1y expired

What this patent protects

一种药物化学领域，作为BCR‑ABL抑制剂的化合物，即式(I)化合物，或其药学上可接受的盐、其制备方法、含有该化合物的药物组合物，并涉及其在制备治疗BCR‑ABL相关疾病的药物中的用途。

USPTO Abstract

一种药物化学领域，作为BCR‑ABL抑制剂的化合物，即式(I)化合物，或其药学上可接受的盐、其制备方法、含有该化合物的药物组合物，并涉及其在制备治疗BCR‑ABL相关疾病的药物中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN114728943B
Jurisdiction
CN
Classification
—
Expires
2024-12-06
Drug substance claim
No
Drug product claim
No
Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.